Published in Psychopharmacology (Berl) on July 01, 2000
The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology (Berl) (2003) 2.13
Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy. Drug Alcohol Depend (2008) 1.15
Evaluation of modafinil effects on cardiovascular, subjective, and reinforcing effects of methamphetamine in methamphetamine-dependent volunteers. Drug Alcohol Depend (2009) 1.11
The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. Pharmacol Biochem Behav (2008) 1.11
Anti-relapse medications: preclinical models for drug addiction treatment. Pharmacol Ther (2009) 1.08
Dual dopamine/serotonin releasers as potential medications for stimulant and alcohol addictions. AAPS J (2007) 1.06
Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction. Exp Clin Psychopharmacol (2008) 1.06
Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate. Pharmacol Ther (2012) 1.04
Acute d-amphetamine pretreatment does not alter stimulant self-administration in humans. Pharmacol Biochem Behav (2007) 1.01
Cardiovascular and subjective effects of repeated smoked cocaine administration in experienced cocaine users. Drug Alcohol Depend (2009) 0.98
Agonist replacement therapy for cocaine dependence: a translational review. Future Med Chem (2012) 0.97
Repeated dosing with oral cocaine in humans: assessment of direct effects, withdrawal, and pharmacokinetics. Exp Clin Psychopharmacol (2009) 0.94
The impact of disulfiram treatment on the reinforcing effects of cocaine: a randomized clinical trial. PLoS One (2012) 0.92
A qualitative and quantitative review of cocaine-induced craving: the phenomenon of priming. Prog Neuropsychopharmacol Biol Psychiatry (2007) 0.88
Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart. Psychopharmacology (Berl) (2012) 0.81
A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med (2000) 6.65
Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA (1999) 5.29
A reinforcement-based therapeutic workplace for the treatment of drug abuse: six-month abstinence outcomes. Exp Clin Psychopharmacol (2001) 4.46
Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry (1997) 3.67
Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther (1994) 2.90
Providing medical care to methadone clinic patients: referral vs on-site care. Am J Public Health (1994) 2.79
A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther (1988) 2.32
Voucher-based reinforcement of cocaine abstinence in treatment-resistant methadone patients: effects of reinforcement magnitude. Psychopharmacology (Berl) (1999) 2.30
Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther (2011) 1.74
Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther (1995) 1.73
Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry (1994) 1.70
Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther (1988) 1.68
Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) (2001) 1.68
Voucher-based reinforcement of opiate plus cocaine abstinence in treatment-resistant methadone patients: effects of reinforcer magnitude. Exp Clin Psychopharmacol (2001) 1.62
Contingent reinforcement for carbon monoxide reduction: within-subject effects of pay amount. J Appl Behav Anal (1984) 1.58
A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend (1995) 1.54
Effect of intravenous injection speed on responses to cocaine and hydromorphone in humans. Psychopharmacology (Berl) (2001) 1.53
The effects of a cooperation contingency on behavior in a continuous three-person environment. J Exp Anal Behav (1976) 1.50
Contingent payment procedures for smoking reduction and cessation. J Appl Behav Anal (1986) 1.45
Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl) (1995) 1.42
Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J Pharmacol Exp Ther (1996) 1.41
Enadoline and butorphanol: evaluation of kappa-agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J Pharmacol Exp Ther (2001) 1.41
Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology (Berl) (2001) 1.41
Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med (1993) 1.41
Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology (Berl) (2000) 1.36
Validity of intravenous drug abusers' self-reported changes in HIV high-risk drug use behaviors. Drug Alcohol Depend (1995) 1.36
Reducing drug use among methadone maintenance clients: contingent reinforcement for morphine-free urines. Addict Behav (1980) 1.35
Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. J Clin Psychopharmacol (1996) 1.35
Facilitation of human tobacco self-administration by ethanol: a behavioral analysis. J Exp Anal Behav (1976) 1.26
Voucher-based reinforcement of attendance by unemployed methadone patients in a job skills training program. Drug Alcohol Depend (1996) 1.24
Contingent methadone delivery: effects on illicit-opiate use. Drug Alcohol Depend (1986) 1.23
Effect of methadone dose contingencies on urinalysis test results of polydrug-abusing methadone-maintenance patients. Drug Alcohol Depend (1986) 1.23
Contingent reinforcement for benzodiazepine-free urines: evaluation of a drug abuse treatment intervention. J Appl Behav Anal (1982) 1.22
The role of behavioral contingency management in drug abuse treatment. NIDA Res Monogr (1984) 1.22
Contingent reinforcement for reduced carbon monoxide levels in cigarette smokers. Addict Behav (1982) 1.20
Human cigarette smoking: manipulation of number of puffs per bout, interbout interval and nicotine dose. J Pharmacol Exp Ther (1982) 1.20
Drug discrimination in human postaddicts: agonist-antagonist opioids. J Pharmacol Exp Ther (1989) 1.19
Reducing benzodiazepine self-administration with contingent reinforcement. Addict Behav (1979) 1.18
Buprenorphine effects in methadone-maintained volunteers: effects at two hours after methadone. J Pharmacol Exp Ther (1995) 1.15
The effects of contingent payment and frequent workplace monitoring on smoking abstinence. Addict Behav (1989) 1.15
Alcohol and secobarbital effects as a function of familial alcoholism: extended intoxication and increased withdrawal effects. Alcohol Clin Exp Res (1991) 1.13
Antisocial personality disorder and HIV infection among intravenous drug abusers. Am J Psychiatry (1993) 1.13
The brief abstinence test: voucher-based reinforcement of cocaine abstinence. Drug Alcohol Depend (2000) 1.12
Contingent reinforcement for reduced breath carbon monoxide levels: target-specific effects on cigarette smoking. Addict Behav (1985) 1.12
Contingency management in methadone maintenance: effects of reinforcing and aversive consequences on illicit polydrug use. Drug Alcohol Depend (1988) 1.11
Early treatment time course of depressive symptoms in opiate addicts. J Nerv Ment Dis (1991) 1.11
Gradual dose taper following chronic buprenorphine. Am J Addict (2001) 1.10
Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berl) (1994) 1.07
A validated liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for quantitation of cocaine and benzoylecgonine in human plasma. J Anal Toxicol (2001) 1.06
Contingency management approaches to drug self-administration and drug abuse: efficacy and limitations. Addict Behav (1981) 1.05
Intravenous drug abusers with antisocial personality disorder: increased HIV risk behavior. Drug Alcohol Depend (1990) 1.04
Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol (1994) 1.04
The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology (Berl) (1997) 1.04
Incongruity between occupational interests and academic skills in drug abusing women. Drug Alcohol Depend (1995) 1.03
Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline. J Pharmacol Exp Ther (1987) 1.02
Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacology (Berl) (2001) 1.01
Alcohol expectancies and changes in beer consumption of first-year college students. Addict Behav (1995) 1.00
Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers. J Pharmacol Exp Ther (1992) 0.99
Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. J Pharmacol Exp Ther (1996) 0.99
Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination. J Pharmacol Exp Ther (2000) 0.99
Reinforcing effects of caffeine in coffee and capsules. J Exp Anal Behav (1989) 0.98
Opioid drug discrimination in humans: stability, specificity and relation to self-reported drug effect. J Pharmacol Exp Ther (1989) 0.98
Validity of patients' self-reported drug use as a function of treatment status. Drug Alcohol Depend (1992) 0.97
Acute physical dependence in man: effects of naloxone after brief morphine exposure. J Pharmacol Exp Ther (1988) 0.96
Drug preference in humans: double-blind choice comparison of pentobarbital, diazepam and placebo. J Pharmacol Exp Ther (1980) 0.96
Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology (Berl) (1988) 0.96
Human coffee drinking: reinforcing and physical dependence producing effects of caffeine. J Pharmacol Exp Ther (1986) 0.96
Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects. Psychopharmacology (Berl) (1997) 0.96
Opioid discrimination in humans: discriminative and subjective effects of progressively lower training dose. Behav Pharmacol (1998) 0.96
Antisocial behavior of intravenous drug abusers: implications for diagnosis of antisocial personality disorder. Am J Psychiatry (1992) 0.95
HIV risk behavior in drug users: increased blood "booting" during cocaine injection. AIDS Educ Prev (1992) 0.95
Antagonist effects of nalbuphine in opioid-dependent human volunteers. J Pharmacol Exp Ther (1989) 0.95
Oral methadone self-administration: effects of dose and alternative reinforcers. Clin Pharmacol Ther (1983) 0.94
A behavioral treatment of alcoholic methadone patients. Ann Intern Med (1978) 0.94
Methadone dose and treatment outcome. Drug Alcohol Depend (1993) 0.93
Acute opioid physical dependence in postaddict humans: naloxone dose effects after brief morphine exposure. J Pharmacol Exp Ther (1989) 0.93
Site of opioid action in the human brain: mu and kappa agonists' subjective and cerebral blood flow effects. Am J Psychiatry (1998) 0.93
Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther (1993) 0.91
Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans. Drug Alcohol Depend (2001) 0.90
Enhancement of cocaine's abuse liability in methadone maintenance patients. Psychopharmacology (Berl) (1996) 0.90
Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend (1990) 0.90
Alcohol and marijuana: comparative dose effect profiles in humans. Pharmacol Biochem Behav (1988) 0.90
Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacology (Berl) (2007) 0.90
Butorphanol-precipitated withdrawal in opioid-dependent human volunteers. J Pharmacol Exp Ther (1988) 0.89
Differential effects of diazepam and pentobarbital on mood and behavior. Arch Gen Psychiatry (1983) 0.89
Buprenorphine, morphine and naloxone effects during ascending morphine maintenance in humans. J Pharmacol Exp Ther (1996) 0.87
Pharmacological influences upon human ethanol self-administration. Adv Exp Med Biol (1977) 0.87
Rapid resumption of cigarette smoking following myocardial infarction: inverse relation to MI severity. Addict Behav (1982) 0.87
Opioid miosis: effects of lighting intensity and monocular and binocular exposure. Drug Alcohol Depend (1993) 0.87
Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. Drug Alcohol Depend (1997) 0.87
Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend (1995) 0.87
Alcohol and drug use by college males as a function of family alcoholism history. Alcohol Clin Exp Res (1990) 0.86
Contingency management interventions: effects on treatment outcome during methadone detoxification. J Appl Behav Anal (1984) 0.86
Relative abuse liability of diazepam and oxazepam: behavioral and subjective dose effects. Psychopharmacology (Berl) (1984) 0.86
Effects of cocaine alone and in combination with mazindol in human cocaine abusers. J Pharmacol Exp Ther (1993) 0.85
Contingency management in methadone treatment: the case for positive incentives. NIDA Res Monogr (1993) 0.85
Dose-related efficacy of levomethadyl acetate for treatment of opioid dependence. A randomized clinical trial. JAMA (1997) 0.85
Acute opioid physical dependence in humans: effect of varying the morphine-naloxone interval. I. J Pharmacol Exp Ther (1989) 0.85
Precipitated withdrawal by pentazocine in methadone-maintained volunteers. J Pharmacol Exp Ther (1993) 0.85
Smoking cessation and relapse among cardiac patients. NIDA Res Monogr (1986) 0.84